The impact of medication on vitamin D status in older individuals

European Journal of Endocrinology

Volumn 166, Issue 3, 2012, Pages 477-485

  Sohl, E ^a   Van Schoor, N M ^a   De Jongh, R T ^a   De Vries, O J ^a   Lips, P ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; COUMARIN DERIVATIVE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PARACETAMOL; POTASSIUM SPARING DIURETIC AGENT; PROTON PUMP INHIBITOR; THIAZIDE DIURETIC AGENT; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ADULT; AGED; AGING; ARTICLE; BLOOD SAMPLING; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYPHARMACY; PRIORITY JOURNAL; SEX DIFFERENCE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

AGE FACTORS; AGED; AGED, 80 AND OVER; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; PROSPECTIVE STUDIES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84857959501     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0917     Document Type: Article

References (37)

1. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocrine Reviews 2001 22 477-501. (doi:10.1210/er.22.4.477)
2. van Schoor NM, Visser M, Pluijm SMF, Kuchuk N, Smit JH & Lips P. Vitamin D deficiency as a risk factor for osteoporotic fractures. Bone 2008 42 260-266. (doi:10.1016/j.bone.2007.11.002)
3. Christensen K, Doblhammer G, Rau R & Vaupel JW. Ageing populations: the challenges ahead. Lancet 2009 374 1196-1208. (doi:10.1016/S0140-6736(09) 61460-4)
4. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE & Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. Journal of the American Medical Association 2002 287 337-344. (doi:10.1001/jama.287.3.337)
5. SFK. Facts and Figs 2010: 2009 in numbers. Foundation for Pharmaceutical Statistics - Website. (cited 2011, June 8). Available from URL: http://www.sfk.nl/publicaties/algemeen/english.html.
6. Ertugrul D, Yavuz B, Cil H, Ata N, Akin K, Kucukazman M, Yalcin A, Dal K, Yavuz B & Tutal E. STATIN-D study: comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxyvitamin D. Cardiovascular Therapeutics 2011 29 146-152. (doi:10.1111/j.1755-5922.2010. 00141.x)
7. Sathyapalan T, Shepherd J, Arnett C, Coady AM, Kilpatrick ES &Atkin SL. Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clinical Chemistry 2010 56 1696-1700. (doi:10.1373/clinchem.2010.144014)
8. Yavuz B, Ertugrul DT, Cil H, Ata N, Akin KO, Yalcin AA, Kucukazman M, Dal K, Hokkaomeroglu MS, Yavuz BB & Tutal E. Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins? Cardiovascular Drugs and Therapy 2009 23 295-299. (doi:10.1007/s10557-009-6181-8)
9. Kulak CAM, Borba VZC, Bilezikian JP, Silvado CE, Paola LD &Boguszewski CL. Bone mineral density and serum levels of 25 OH vitamin D in chronic users of antiepileptic drugs. Arquivos de Neuro-Psiquiatria 2004 62 940-948. (doi:10.1590/S0004-282X2004000600003)
10. Misra A, Aggarwal A, Singh O & Sharma S. Effect of carbamazepine therapy on vitamin D and parathormone in epileptic children. Pediatric Neurology 2010 43 320-324. (doi:10.1016/j.pediatrneurol.2010.05.013)
11. Deeg DJH, van Tilburg T, Smit JH & de Leeuw ED. Attrition in the Longitudinal Aging Study Amsterdam. The effect of differential inclusion in side studies. Journal of Clinical Epidemiology 2002 55 319-328. (doi:10.1016/S0895- 4356(01)00475-9)
12. Huisman M, Poppelaars J, van der Horst M, Beekman A, Brug J, van Tilburg T & Deeg D. Cohort profile: the Longitudinal Aging Study Amsterdam. International Journal of Epidemiology 2011 40 868-876. (doi:10.1093/ije/dyq219)
13. WHO collaborating Centre for drug Statistics Methodology - Website (cited 2011, April 27); Available from URL: http://www.whocc.no/atc-ddd-index/.
14. Freire AC, Basit AW, Choudhary R, Piong CW & Merchant HA. Does sex matter? The influence of gender on gastrointestinal physiology and drug delivery. International Journal of Pharmaceutics 2011 415 15-28. (doi:10.1016/j.ijpharm.2011.04.069)
15. Garretsen HFL. In Probleemdrinken, Prevalentiebepaling, Beinvloedende Factoren en Preventiemogelijkheden, Theoretische Overwegingen en Onderzoek in Rotterdam (dissertation in Dutch). Lisse, The Netherlands: Swets and Zeitlinger, 1983.
16. Manjunath G, Sarnak MJ & Levey AS. Prediction equations to estimate glomerular filtration rate: an update. Current Opinion in Nephrology and Hypertension 2001 10 785-792. (doi:10.1097/00041552-200111000-00009)
17. Stel VS, Smit JH, Pluijm SMF, Visser M, Deeg DJH & Lips P. Comparison of the LASA Physical Activity Questionnaire with a 7-day diary and pedometer. Journal of Clinical Epidemiology 2004 57 252-258. (doi:10.1016/j.jclinepi.2003. 07.008)
18. Lang PO, Michel JP & Zekry D. Frailty syndrome: a transitional state in a dynamic process. Gerontology 2009 55 539-549. (doi:10.1159/000211949)
19. Rejnmark L, Vestergaard P, Heickendorff L, Andreasen F &Mosekilde L. Effects of long-term treatment with loop diuretics on bone mineral density, calcitropic hormones and bone turnover. Journal of Internal Medicine 2005 257 176-184. (doi:10.1111/j.1365-2796.2004.01434.x)
20. Rejnmark L, Vestergaard P, Heickendorff L, Andreasen F &Mosekilde L. Effects of thiazide- and loop-diuretics, alone or in combination, on calcitropic hormones and biochemical bone markers: a randomized controlled study. Journal of Internal Medicine 2001 250 144-153. (doi:10.1046/j.1365-2796.2001.00868.x)
21. Mikhail N. Clinical significance of vitamin D deficiency in primary hyperparathyroidism, and safety of vitamin D therapy. Southern Medical Journal 2011 104 29-33. (doi:10.1097/SMJ.0b013e3181fcd772)
22. Jennings BH, Andersson KE & Johansson SA. The assessment of the systemic effects of inhaled glucocorticosteroids. The effects of inhaled budesonide vs oral prednisolone on calcium metabolism. European Journal of Clinical Pharmacology 1991 41 11-16. (doi:10.1007/BF00280099)
23. Janssens W, Bouillon R, Claes B, Carremans C, Lehouck A, Buysschaert I, Coolen J, Mathieu C, Decramer M & Lambrechts D. Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. Thorax 2010 65 215-220. (doi:10.1136/thx.2009.120659)
24. Kunisaki KM & Rector TS. Vitamin D and responses to inhaled fluticasone in severe chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 2011 6 29-34. (doi:10.2147/COPD.S15358)
25. Boucher BJ. Inadequate vitamin D status: does it contribute to the disorders comprising syndrome 'X'? British Journal of Nutrition 1998 79 315-327. (doi:10.1079/BJN19980055)
26. Takiishi T, Gysemans C, Bouillon R & Mathieu C. Vitamin D and diabetes. Endocrinology and Metabolism Clinics of North America 2010 39 419-446. (doi:10.1016/j.ecl.2010.02.013)
27. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Current Drug Metabolism 2008 9 310-322. (doi:10.2174/138920008784220664)
28. Levin TT, Bakr MH & Nikolova T. Case report: delirium due to a diltiazem-fentanyl CYP3A4 drug interaction. General Hospital Psychiatry 2010 32 648. (doi:10.1016/j.genhosppsych.2010.08.003)
29. McFarlane SI, Kumar A & Sowers JR. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. American Journal of Cardiology 2003 91 30H-37H. (doi:10.1016/S0002- 9149(03)00432-6)
30. Werner C, Baumhakel M, Teo KK, Schmieder R, Mann J, Unger T, Yusuf S & Bohm M. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clinical Research in Cardiology 2008 97 418-431. (doi:10.1007/s00392-008-0668-3)
31. Feneis JF & Arora RR. Role of vitamin D in blood pressure homeostasis. American Journal of Therapeutics 2010 17 e221-e229. (doi:10.1097/MJT.0b013e3181d16999)
32. Snijder MB, Lips P, Seidell JC, Visser M, Deeg DJH, Dekker JM &van Dam RM. Vitamin D status and parathyroid hormone levels in relation to blood pressure: a population-based study in older men and women. Journal of Internal Medicine 2007 261 558-565. (doi:10.1111/j.1365-2796.2007.01778.x)
33. Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K, Lichtenstein AH, Lau J & Balk EM. Systematic review: vitamin D and cardiometabolic outcomes. Annals of Internal Medicine 2010 152 307-314.
34. Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, Lieben L, Mathieu C & Demay M. Vitamin D and human health: lessons fromvitamin D receptor nullmice. Endocrine Reviews 2008 29 726-776. (doi:10.1210/er.2008-0004)
35. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S & Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. Canadian Medical Association Journal 2008 179 319-326. (doi:10.1503/cmaj.071330)
36. Hansen KE, Jones AN, Lindstrom MJ, Davis LA, Ziegler TE, Penniston KL, Alvig AL & Shafer MM. Do proton pump inhibitors decrease calcium absorption? Journal of Bone and Mineral Research 2010 25 2786-2795. (doi:10.1002/jbmr.166)
37. Rejnmark L, Vestergaard P, Heickendorff L & Mosekilde L. Simvastatin does not affect vitamin D status, but low vitamin D levels are associated with dyslipidemia: results from a randomised, controlled trial. International Journal of Endocrinology 2010 2010 957174. (doi:10.1155/2010/957174)